首页> 外文期刊>Archives of disease in childhood >Current therapy for bronchiolitis
【24h】

Current therapy for bronchiolitis

机译:细支气管炎的当前治疗方法

获取原文
获取原文并翻译 | 示例
       

摘要

Bronchiolitis is a common, self-limiting, seasonal viral respiratory tract infection in infancy accounting for the majority of hospital admissions in this age group. Supportive care is the mainstay of treatment, concentrating on fluid replacement, gentle suctioning of nasal secretions, prone position (if in hospital), oxygen therapy and respiratory support if necessary. There is a long history of pharmacological agents offering no benefit in acute bronchiolitis. More recently, nebulised epinephrine has been demonstrated to offer short term benefits, while two stratagems have shown promise in decreasing risk of hospitalisation and length of hospital stay. The combination of oral dexamethasone with nebulised epinephrine potentially decreases the need for hospitalisation, while nebulised 3% hypertonic saline mixed with a bronchodilator decreases the length of hospitalisation. Although both stratagems appear safe and well tolerated, their role in clinical practice remains unclear.
机译:毛细支气管炎是婴儿期的一种常见的,自限性的季节性病毒性呼吸道感染,占该年龄组住院的大多数。支持性护理是治疗的主要内容,重点在于补充体液,轻柔地吸鼻分泌物,俯卧位(如果在医院中),必要时进行氧气治疗和呼吸支持。长期以来没有药物对急性毛细支气管炎有益。最近,已证明雾化的肾上腺素具有短期益处,而两种策略已证明有望降低住院风险和住院时间。口服地塞米松与雾化的肾上腺素的组合可能会减少住院的需要,而雾化的3%高渗盐水与支气管扩张剂混合会缩短住院的时间。尽管这两种策略都看似安全且耐受性良好,但它们在临床实践中的作用仍不清楚。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号